Nathan Kline Institute for Psychiatric Research — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Nathan Kline Institute for Psychiatric Research appears in 34 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials34

Recruiting shown1

Roles2

SourceClinicalTrials.gov

Clinical trials

34 shown

Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual PathwaysNCT07469384 · lead sponsor · 2026-02-01

Sodium Butyrate For Improving Cognitive Function In SchizophreniaNCT02654405 · lead sponsor · 2016-04-01

D-serine and Cognitive Remediation in SchizophreniaNCT02156908 · lead sponsor · 2014-08-01

Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in SchizophrenicNCT02128919 · lead sponsor · 2012-04-01

N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in SchizophreniaNCT01474395 · lead sponsor · 2012-03-01

Biomarkers in SchizophreniaNCT00817336 · lead sponsor · 2009-06-01

D-serine for the Schizophrenia ProdromeNCT00826202 · lead sponsor · 2009-03-01

Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and PredictorsNCT00802919 · lead sponsor · 2008-09-01

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight GainNCT00709202 · lead sponsor · 2008-07-01

Sodium Oxybate in Schizophrenia With InsomniaNCT00594256 · lead sponsor · 2008-05-01

Metformin for Weight Loss in SchizophreniaNCT01177709 · lead sponsor · 2008-05-01

Conversion to Antipsychotic MonotherapyNCT01368458 · lead sponsor · 2007-12-01

Varenicline Effects In Schizophrenic SmokersNCT00548470 · lead sponsor · 2007-06-01

Safety and Effectiveness of D-serine in SchizophreniaNCT00322023 · lead sponsor · 2006-03-01

Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With SchizophreniaNCT00231894 · lead sponsor · 2005-05-01

Effect of High-Dose B-Complex Vitamins on the Symptoms of SchizophreniaNCT00403247 · lead sponsor · 2004-07-01

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid MetabolismNCT00287820 · lead sponsor · 2004-02-01

Cognitive Skills Training Using Computer for Patients With Severe Mental IllnessNCT01036282 · lead sponsor · 2003-02-01

Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and HostilityNCT00308360 · lead sponsor · 1999-09-01

Clozapine and Olanzapine Treatment of AggressionNCT01123408 · lead sponsor · 1999-06-01

D-serine AudRem: R33 PhaseNCT05046353 · collaborator · 2022-12-01

D-serine Augmentation of NeuroplasticityNCT03711500 · collaborator · 2019-03-13

Evaluation of a Visual Remediation Intervention for SchizophreniaNCT03117452 · collaborator · 2017-02-23

Can Cognitive Training Decrease Reactive Aggression?NCT03623477 · collaborator · 2016-08-16

Remediation of Auditory Recognition in Schizophrenia With tDCSNCT02869334 · collaborator · 2016-06-01

Transcranial Direct Current Stimulation (tDCS) as a Treatment for Cognitive Deficits in SchizophrenicNCT02748083 · collaborator · 2015-12-01

Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?NCT01964404 · collaborator · 2014-07-01

Safety Study of Pyridostigmine in Heart FailureNCT01415921 · collaborator · 2011-10-01

Org 24448 (Ampakine) for Cognitive Deficits in SchizophreniaNCT00425815 · collaborator · 2009-04-01

A Multicenter Study of NAP (AL-108) in SchizophreniaNCT00505765 · collaborator · 2007-07-01

Treatment Study for Cognitive Deficits in SchizophreniaNCT00505076 · collaborator · 2007-07-01

Brain Activation Patterns in Schizophrenia After Computerized Cognitive Skills TrainingNCT00431223 · collaborator · 2006-09-01

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective DisorderNCT00297947 · collaborator · 2004-12-01

Adjunctive Treatment for Decreasing Symptoms of SchizophreniaNCT00222235 · collaborator · 2000-01-01

Drugs studied in this sponsor's trials

12 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Nathan Kline Institute for Psychiatric Research as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

olanzapine2

varenicline2

clozapine1

dronabinol1

glycine1

haloperidol1

metformin1

pioglitazone1

olanzapine RxCUI 61381 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials varenicline RxCUI 591622 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials clozapine RxCUI 2626 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial dronabinol RxCUI 10402 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial glycine RxCUI 4919 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial haloperidol RxCUI 5093 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial metformin RxCUI 6809 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial pioglitazone RxCUI 33738 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial pyridostigmine bromide RxCUI 9001 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial quetiapine RxCUI 51272 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial risperidone RxCUI 35636 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial sodium oxybate RxCUI 9899 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor20

collaborator14

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.